Dr. Radhakrishnan Ramchandren, MD

Dr. Ramchandren practices at Reading Hospital in West Reading, Pennsylvania, part of Tower Health.

Dr. Ramchandren's NPI, 1700089331, was assigned on June 10, 2007. Dr. Ramchandren holds Michigan license 4301085844.

Dr. Ramchandren's primary practice is Reading Hospital, at 420 S 5th Avenue, West Reading, PA 19611 in Berks County. The practice phone is (610) 988-8000.

Dr. Ramchandren's primary practice is Reading Hospital in West Reading, Pennsylvania, part of Tower Health. The medical group on file is Reading Hospital Cardiology - West Reading. Dmand AI also links Dr. Ramchandren to 3 more medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Ramchandren practices. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Ramchandren's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Ramchandren is licensed in Michigan.

CMS data shows 215 Medicare services from Dr. Ramchandren across 4 procedure codes in 2024, for 102 Medicare patients. Medicare paid $14,290 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 102 Medicare patients who saw Dr. Ramchandren in 2024. The largest group is 65 to 74, with 51 patients. 75% of them have high blood pressure, and 73% have high cholesterol. 12% are also on Medicaid. Their average risk score is 2.59, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Ramchandren's median patient age at 66, with 54% women.

In 2024, Dr. Ramchandren wrote 328 Medicare Part D claims for 61 patients. 69% of them were for generic drugs. CMS names the drug for 143 of them, across 8 drugs with 11 or more claims each, at $906,797 in total drug cost. In 2023, CMS named 388 claims across 17 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 96 out of 100 for Dr. Ramchandren for performance year 2024, reported through an alternative payment model (APM). Dr. Ramchandren accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 50 papers to Dr. Ramchandren, published from 2012 to 2023. 2019 was the busiest year, with 9. The most frequent topics are Hodgkin Disease, Brentuximab Vedotin and Antineoplastic Combined Chemotherapy Protocols. Dr. Ramchandren has published most often in J Clin Oncol. Dr. Ramchandren's most frequent co-authors are Tatyana A. Feldman, MD, Andre H. Goy, MD and Ranjana Advani, MD.

Dmand AI links Dr. Ramchandren to 10 clinical trials, 8 of them phase 2 studies. 6 are still active or recruiting. Conditions studied include Hodgkin Disease, Lymphoma and Enteropathy-Associated T-Cell Lymphoma. Seagen, a wholly owned subsidiary of Pfizer sponsors the most, 2.

CMS Open Payments shows 596 general payments to Dr. Ramchandren from 58 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 41% of the total. GlaxoSmithKline, LLC. paid the most, $87,537. It also lists 7 research payments totaling $6,510 from 2016 to 2025.